LASAACI 2023 Fall Symposium

Los Angeles, CA US
September 9, 2023

The Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI) is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology and the LASAACI.  The 2023 program is a four-hour event with speakers covering the topics of Mast Cell Disorders, Chronic Urticaria, Drug Allergy and Immunity.  The LASAACI Faculty are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendees' practices and will provide attendees exposure to new content.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Los Angeles Society of Allergy, Asthma, and Clinical Immunology.  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours. 

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals.

Learning Objectives

At the conclusion of this activity learners should be able to…

1.    Integrate basic genetic principles into the evaluation and management of patients with inborn immune disorders
2.    Evaluate and manage patients with drug allergy
3.    Describe the differential diagnosis in patients being worked up for mast cell disorders 
4.    Describe the clinical characteristics of patients with hereditary alpha tryptasemia 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
09/09/2023
Course expires: 
12/31/2024
Event starts: 
09/09/2023 - 6:30am CDT
Event ends: 
09/09/2023 - 1:30pm CDT
Add to calendar: 
Rating: 
0

LASAACI 2023 Fall Symposium

Saturday, September 9, 2023

6:30AM-8:20AM Registration, Exhibits & Coffee Break

8:20AM-8:30AM Welcome and Introduction, Sheila Bonilla, MD

8:30AM-9:30AM Inborn Errors of Immunity: Fact vs Fiction, Mary Beth Fasano, MD, MSPH

9:30AM-10:30AM Mast Cell Disorders and Alpha-Tryptasemia, Jonathan Lyons, MD

10:30AM-11:30AM Buffet Brunch, Exhibits, Posters

11:30AM-12:30PM Chronic Urticaria Update—Scratching Below the Surface, David Lang, MD

12:30PM-1:30PM Drug Allergy: Beyond the Basics, Anna R. Wolfson, MD

1:30PM Adjourn

Skirball Cultural Center
2701 N. Sepulveda Blvd.
Los Angeles, CA 90049
United States

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All identified relevant financial relationships with ineligible companies have been mitigated.

Jonathan Corren, MD, Planner
Advisor: AstraZeneca, Regeneron, Sanofi
Speaker: AstraZeneca, GSK, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca
Independent contractor: Novartis, Regeneron, Teva

Rita Kachru, MD, Planner
Researcher: Aimmune

Sonal Patel, MD, Planner
Speaker: Sanofi/Regeneron

David Lang, MD, Speaker
Speaker: Sanofi/Regeneron, AstraZeneca
Researcher: Sanofi/Regeneron, Genentech, Novartis
Consultant: Genentech, Novartis, Blueprint

Sheila M. Bonilla, MD, Planner - No relevant financial relationships with ineligible companies to disclose
Dean Chiang, MD, Planner - No relevant financial relationships with ineligible companies to disclose
Edward Hu, MD, Planner - No relevant financial relationships with ineligible companies to disclose
Caroline Spagnola, MD, Planner- No relevant financial relationships with ineligible companies to disclose
Andrew K. Wong, MD, Planner- No relevant financial relationships with ineligible companies to disclose
Joseph Yusin, MD, Planner- No relevant financial relationships with ineligible companies to disclose
Karol Anderson, MBA, Planner- No relevant financial relationships with ineligible companies to disclose
Mary Beth Fasano, MD, Speaker- No relevant financial relationships with ineligible companies to disclose
Jonathan Lyons, MD, Speaker- No relevant financial relationships with ineligible companies to disclose
Anna R. Wolfson, MD, Speaker- No relevant financial relationships with ineligible companies to disclose

 

 

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.